CAELYXA in English translation

• caelyx

Examples of using Caelyxa in Croatian and their translations into English

dob u ispitivanom rasponu(21- 75 godina) ne mijenja značajno farmakokinetiku Caelyxa.
the range tested(21-75 years) does not significantly alter the pharmacokinetics of Caelyx.

vrijednosti plazmatske koncentracije i AUC Caelyxa koje uglavnom predstavljaju pegilirani liposomalni doksorubicinklorid(sadrži 90% do 95% izmjerenog doksorubicina),
the plasma concentration and AUC values of Caelyx which represent mostly pegylated liposomal doxorubicin hydrochloride(containing 90% to 95% of the measured doxorubicin)

Klinička ispitivanja u bolesnika s Kaposijevim sarkomom povezanim s AIDS-om liječenih dozom od 20 mg/m2 Caelyxa pokazuju da je mijelosupresija bila najčešća nuspojava koja se smatra povezanom s Caelyxom i koja se javljala vrlo često u približno jedne polovice bolesnika.
Clinical studies on AIDS-KS patients treated at 20 mg/m2 with Caelyx show that myelosuppression was the most frequent undesirable effect considered related to Caelyx occurring very commonly in approximately one-half of the patients.

njihov muški partner primaju Caelyx te tijekom šest mjeseci nakon prestanka terapije Caelyxa vidjeti dio 5.3.
their male partner are receiving Caelyx and in the six months following discontinuation of Caelyx therapy see section 5.3.

U bolesnika s multiplim mijelomom koji se liječe Caelyxom u kombinaciji s bortezomibom i koji razviju PPE ili stomatitis, dozu Caelyxa potrebno je prilagoditi kako je opisano u gornjoj tablici 1, odnosno 2.
For multiple myeloma patients treated with Caelyx in combination with bortezomib who experience PPE or stomatitis, the Caelyx dose should be modified as described in Table 1 and 2 above respectively.

Budući da analiza baze podataka o sigurnosti primjene nakon stavljanja lijeka u promet ne pokazuje da značanu nefrotoksičnost Caelyxa, navedeni nalazi dobiveni u majmuna možda nisu važni za procjenu rizika u bolesnika.
Since an evaluation of the post-marketing safety database for Caelyx in patients has not suggested a significant nephrotoxicity liability of Caelyx, these findings in monkeys may not have relevance to patient risk assessment.

Štoviše, u kontroliranom kliničkom ispitivanju Caelyxa u usporedbi s topotekanom, incidencija sepse povezane s liječenjem bila je znatno manja u bolesnica s karcinomom jajnika liječenih Caelyxom nego u skupini liječenoj topotekanom.
Moreover, in a controlled clinical trial of Caelyx vs. topotecan, the incidence of treatment related sepsis was substantially less in the Caelyx-treated ovarian cancer patients as compared to the topotecan treatment group.

Cilj određen planom ispitivanja bio je pokazati neinferiornost Caelyxa u odnosu na doksorubicin
The protocol-specified objective of demonstrating non-inferiority between Caelyx and doxorubicin was met, the hazard ratio(HR)

Za vrijeme infuzije Caelyxa mogu nastati sljedeće reakcije:
During the infusion of Caelyx, the following reactions may occur:

U bolesnika liječenih kombiniranom terapijom Caelyxa i bortezomiba nastupilo je značajno poboljšanje vremena do napredovanja bolesti(TTP)
There was a significant improvement in the primary endpoint of time to progression(TTP) for patients treated with combination therapy of Caelyx plus bortezomib compared to patients treated with bortezomib monotherapy as indicated by a risk reduction(RR)

Nuspojave identificirane tijekom postmarketinškog iskustva s Caelyxom.
Adverse drug reactions identified during the post-marketing experience with Caelyx.

Ispitivanje je pokazalo da Caelyx u jednokratnoj intravenskoj dozi koja je više nego dvaput veća od kliničke doze toksično djeluje na bubrege u majmuna.
A study has shown that Caelyx at a single intravenous dose of over twice the clinical dose produces renal toxicity in monkeys.

Vaš partner uzimate Caelyx, kao i tijekom šest mjeseci nakon prestanka liječenja Caelyxom..
your partner are taking Caelyx and in the six months following discontinuation of Caelyx treatment.

Budući da djelatna tvar doksorubicinklorid u Caelyxu može prouzročiti urođene mane,
Because the active ingredient doxorubicin hydrochloride in Caelyx may cause birth defects,

Caelyx se može primijeniti u bolesnika s metastazama u jetri i istovremeno povišenom razinom bilirubina
Caelyx can be administered to patients with liver metastases with concurrent elevation of bilirubin

Caelyx se primjenjuje u dozi od 30 mg/m² u obliku jednosatne infuzije koja se daje 4. dana trotjednog protokola s bortezomibom, neposredno nakon infuzije bortezomiba.
Caelyx is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion.

Caelyx se primjenjuje intravenski u dozi od 50 mg/m2 jedanput svaka 4 tjedna, do progresije bolesti odnosno dok bolesnik podnosi liječenje.
Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.

Caelyx se također primjenjuje u kombinaciji s drugim lijekom,
Caelyx is also used in combination with another medicine,

Način rukovanja lijekom Caelyx i njegovo uklanjanje moraju biti sukladni načinu rukovanja
Caelyx must be handled and disposed of in a manner consistent with that of other

Način rukovanja Caelyxom i njegovo uklanjanje moraju biti sukladni načinu rukovanja i uklanjanja drugih antitumorskih lijekova.
Caelyx must be handled and disposed of in a manner consistent with that of other anticancer medicinal products.